STAT+: Pharmalittle: We’re reading about EMA plans for GLP-1 shortages, Walgreens store closings, and more
Good morning, everyone, and how are you today? The heat continues to rise here on…
Category: pharmalittle
STAT+: Pharmalittle: We’re reading about rejection of an AbbVie Parkinson’s drug, PBM markups on mail order, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Novo’s Wegovy approval in China, a Merck KGaA cancer trial failure, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: We’re reading about a plan for Medicare coverage of Wegovy, an Alnylam heart drug, and more
Good morning, everyone, to another working week. We hope the weekend respite was relaxing and…
STAT+: Pharmalittle: We’re reading about FDA approval for Sarepta drug, MSF closing access campaign and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Lilly lawsuits, Novo Nordisk fires and much more
Rise and shine, everyone, another hot day is on the way. The forecast – at…
STAT+: Pharmalittle: We’re reading about a Merck pneumococcal shot, Kansas suing Pfizer, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: Pharmalittle: We’re reading about an ‘unaffordable’ Novartis drug, a new patent office rule, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about abortion pill access, employer coverage of GLP-1 drugs and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Pfizer drug for Duchenne, bird flu vaccines for cows, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, an EU contract for bird flu vaccine, and more
Greetings from London, with STAT reporter Andrew Joseph here filling in for Ed. We’re dealing…
STAT+: Pharmalittle: We’re reading about a Moderna Covid-flu vaccine, a paused Pfizer study, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Lilly’s Alzheimer’s drug, the GSK-Elsie deal, and more
Good morning, Jason Mast here filling in for Ed. Today, we’re sipping a hot cup…
STAT+: Pharmalittle: We’re reading about the aftermath of FDA vote on MDMA, rising pharma layoffs, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about MDMA ‘no’ votes, a Gilead settlement, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about an FDA meeting on MDMA, a new obesity pill, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Pharmalittle: We’re reading about Zantac lawsuits, worries over MDMA for PTSD, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about docs paid for endorsements, Novartis suing Maryland, and lots more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a deal for a Moderna bird flu shot, NIH trial shortcomings, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a Merck deal, weight loss drugs, and lots more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more
It’s an honor to fill in for Ed Silverman this morning. There is only one…
STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more
Top of the morning to you. I’m filling in for Ed Silverman this morning, which…
STAT+: Pharmalittle: We’re watching a ban compounded versions of GLP-1s, a Biogen acquisition, and more
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences…
STAT+: Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more
Good morning from the Pharmalittle campus, where I’m filling in for Ed. Normally, I’m the…
STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more
Good morning from STAT reporter Andrew Joseph, filling in here for Mr. Pharmalot. We’ve recently…
STAT+: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Roche obesity drug, an experimental Lilly insulin, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: Pharmalittle: We’re reading about fake studies, AbbVie investing in psychedelics, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT+: Pharmalittle: We’re reading about Pfizer’s DTC platform, Sandoz’s feud with a U.K. trade group, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Pharmalittle: We’re reading about FDA dithering on pharma patents, WHO pandemic talks, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Sanofi licensing Novavax’s Covid shot, Moderna’s RSV vaccine, and more
Hello there and happy Friday from STAT’s London outpost, where the weekend is mere hours…
STAT+: Pharmalittle: We’re reading about Takeda restructuring, Pfizer settling Zantac suits, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about a boy dying in Pfizer trial; AstraZeneca yanking Covid shot, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Pharmalittle: We’re reading about MDMA for PTSD, a CRISPR treatment for blindness, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Pharmalittle: We’re reading about FTC reviewing Novo-Catalent deal, Amneal opioid settlement, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about Wegovy and Ozempic sales, rising pharma layoffs, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about FTC fighting ‘junk’ patents, Pfizer direct-to-consumer plans, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Pharmalittle: We’re reading about a Medicare price-negotiation ruling, pharma’s slipping reputation, and more
Rise and shine, everyone, another busy day is on the way. We can tell thanks…
STAT+: Pharmalittle: We’re reading about MorphoSys drug risks, an AstraZeneca admission, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about Cigna biosimilar plans, a Vertex deal in South Africa, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about a Senate probe into Novo pricing, a new UTI antibiotic, and more
Rise and shine, everyone, another busy day is on the way. We can tell because…
STAT+: Pharmalittle: We’re reading about GLP-1 spending, biosimilar patient costs, and more
Hello, everyone, and welcome to the middle of the week. Congratulations on making it this…
STAT+: Pharmalittle: We’re reading about Lilly buying a plant, a Pfizer antibiotic, and more
Top of the morning to you, and a fine one it is. There is nothing…
STAT+: Pharmalittle: We’re reading about an OptumRx contract, 340B dispute resolution, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: We’re reading about plans for generic Wegovy, cough syrup warnings, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: We’re reading about BIO’s China challenge, Zepbound shortages, and more
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are…
STAT+: Pharmalittle: We’re reading about Lilly’s Zepbound for sleep apnea, the FDA budget, and more
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…